Cantor Fitzgerald Increases Earnings Estimates for Alector

Alector, Inc. (NASDAQ:ALEC - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Alector in a research note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.02) per share for the year, up from their previous forecast of ($2.55). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The firm had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million.

Several other analysts have also issued reports on ALEC. Bank of America lowered shares of Alector from a "neutral" rating to an "underperform" rating and lowered their price target for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. Stifel Nicolaus downgraded shares of Alector from a "buy" rating to a "hold" rating and set a $4.00 target price on the stock. in a research note on Monday, December 16th. Morgan Stanley lowered Alector from an "equal weight" rating to an "underweight" rating and reduced their price objective for the company from $10.00 to $3.00 in a research report on Tuesday, November 26th. Mizuho cut shares of Alector from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $9.00 to $2.50 in a research report on Tuesday, December 17th. Finally, HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Alector in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $3.75.

Alector Stock Performance

ALEC stock traded up $0.10 during mid-day trading on Monday, hitting $1.55. The company had a trading volume of 650,084 shares, compared to its average volume of 716,171. Alector has a 12 month low of $1.30 and a 12 month high of $7.10. The stock's fifty day moving average price is $1.75 and its two-hundred day moving average price is $3.43. The firm has a market cap of $153.58 million, a PE ratio of -0.91 and a beta of 0.61.

Institutional Investors Weigh In On Alector

Several large investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Alector by 12.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,570 shares of the company's stock valued at $303,000 after acquiring an additional 17,509 shares during the last quarter. Velan Capital Investment Management LP bought a new position in Alector during the 4th quarter worth about $104,000. Squarepoint Ops LLC purchased a new position in Alector during the 4th quarter valued at about $25,000. Two Sigma Advisers LP increased its position in Alector by 8.9% during the 4th quarter. Two Sigma Advisers LP now owns 429,900 shares of the company's stock valued at $813,000 after purchasing an additional 35,000 shares during the period. Finally, Two Sigma Investments LP raised its holdings in shares of Alector by 55.4% in the 4th quarter. Two Sigma Investments LP now owns 407,989 shares of the company's stock valued at $771,000 after purchasing an additional 145,467 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.